v3.26.3
Schedule of Reconciliation of Theoretical Income Tax Expense to Actual Income Tax Expense (Details) - Chemomab Therapeutics Ltd [Member] - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Loss before income taxes $ (2,165) $ (2,057) $ (3,938) $ (5,380) $ (8,995) $ (13,945) $ (24,221)
Share-based compensation         $ 120    
Share-based compensation, percentage         (1.30%)    
Other         $ 5    
Nontaxable income or nondeductible expenses:, percentage         (0.10%)    
Change in valuation allowance         $ 2,297    
Change in valuation allowance, percentage         (25.50%)    
Other         $ (344)    
Other, percentage         3.80%    
Foreign tax effects         $ (9)    
Foreign tax effects, percentage         0.10%    
Actual income tax expense (Benefit)
Actual income tax expenses, percentage         0.00%    
Change in temporary differences for which deferred taxes were not recognized           858 (1,177)
Tax rate differential           9 10
Non-deductible expenses           148 346
Losses and other items for which a valuation allowance was provided or benefit from loss carryforwards           2,192 6,392
Income Tax Jurisdiction, Domestic Federal [Member]              
Loss before income taxes         $ (2,069) $ (13,945) $ (24,221)
Israeli statutory income tax rate, percentage         23.00% 23.00% 23.00%
Theoretical tax benefit           $ (3,207) $ (5,571)